Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04223791 · ClinicalTrials.gov registry record · Phase 3
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
A Phase 3 study of HIV Infection, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 643
- Enrollment target
- 20
- Study locations
NCT04223791 is a Phase 3 study of HIV Infection that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 643 participants, above the 234-participant average among 73 other HIV Infection trials with a reported enrollment target (175% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT04223791, a Phase 3 study of HIV Infection, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 643 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodeficiency virus -1 (HIV-1)-infected participants virologically suppressed on a regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that a switch to MK-8591A will be non-inferior to continued treatment with BIC/FTC/TAF as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Participants who benefit from their assigned intervention (as determined by investigator) will be able to continue treatment through a 24-week study extension.
Conditions Studied
Interventions
- DRUG BIC/FTC/TAF
- DRUG DOR/ISL
- DRUG Placebo to BIC/FTC/TAF
- DRUG Placebo to FDC DOR/ISL
Study Locations (20)
California
- Pacific Oaks Medical Group ( Site 2765) - Beverly Hills
- Men's Health Foundation ( Site 2749) - Los Angeles
- Kaiser Permanente Los Angeles Medical Center ( Site 2775) - Los Angeles
- Eisenhower Medical Center ( Site 2744) - Palm Springs
- University of California, Davis, Division of ID Research ( Site 2702) - Sacramento
- Zuckerberg San Francisco General Hospital UCSF ( Site 2743) - San Francisco
Florida
- TheraFirst Medical Center ( Site 2742) - Fort Lauderdale
- Midway Immunology and Research ( Site 2759) - Ft. Pierce
- The Kinder Medical Group ( Site 2739) - Miami
- AHF South Beach ( Site 2780) - Miami Beach
- Orlando Immunology Center ( Site 2734) - Orlando
- Triple O Research Institute, P.A. ( Site 2755) - West Palm Beach
Georgia
- Augusta University ( Site 2752) - Augusta
- Infectious Disease Specialists Of Atlanta PC ( Site 2719) - Decatur
- Mercer University ( Site 2738) - Macon
- Chatham County Health Department ( Site 2731) - Savannah
Arizona
- Pueblo Family Physicians ( Site 2717) - Phoenix
District of Columbia
- Whitman-Walker Clinic ( Site 2728) - Washington D.C.
Minnesota
- Hennepin County Medical Center ( Site 2733) - Minneapolis
Missouri
- Kansas City CARE Clinic ( Site 2718) - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04223791
The ClinicalTrials.gov registry entry for NCT04223791 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 234-participant average among 73 other HIV Infection trials with a reported enrollment target (175% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 4 interventions - of which BIC/FTC/TAF is the first listed.
NCT04223791 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04223791 about?
NCT04223791 is a clinical study titled "Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)". This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodeficiency virus -1 (HIV-1)-infected participants virologically suppressed on a regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). Th...
What is the current status of trial NCT04223791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 643 participants. The study started on 2020-02-18. Estimated completion is 2025-02-27.
What conditions does trial NCT04223791 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT04223791?
The interventions under investigation include: BIC/FTC/TAF (DRUG), DOR/ISL (DRUG), Placebo to BIC/FTC/TAF (DRUG), Placebo to FDC DOR/ISL (DRUG).
Who is sponsoring clinical trial NCT04223791?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04223791 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Study of Three NNRTI-Sparing HAART Regimens
COMPLETED · Phase 3
-
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
COMPLETED · Phase 3
-
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
COMPLETED · Phase 3
-
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
COMPLETED · Phase 3
-
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.